Canadian health leaders launch digital initiative to prepare for new wave of Alzheimer's therapies
12/02/2025
A coalition of Canada's top dementia experts will test the Foresight™ platform by Canadian-based Perceiv Research Inc., with inaugural support from Eli Lilly Canada and Novo Nordisk Canada, to enhance patient safety and support access.
MONTREAL, QC – Following Health Canada’s historic approval of anti-amyloid therapy for Alzheimer’s disease, a coalition of Canada’s leading dementia experts is launching the Canadian Alzheimer's Readiness (CARE) Initiative to prepare the nation's healthcare system for the arrival of new Alzheimer's disease-modifying therapies.
With support from Eli Lilly Canada Inc. and Novo Nordisk Canada Inc., researchers will be testing the Foresight™ digital health platform developed by Canadian-based Perceiv Research Inc., across clinical sites in Ontario, Quebec, Alberta, and British Columbia, to create a blueprint for safe and standardized patient care.
The Challenge: A Paradigm Shift in Alzheimer’s Management
The introduction of disease-modifying therapies for Alzheimer's disease represents the most significant shift in the management of Alzheimer’s disease in decades. The field is rapidly moving from a discipline focused on diagnosis and symptom management to one of active and complex therapeutic intervention.
This transformation, now underway in Canada, demands a level of diagnostic precision, patient screening, and ongoing safety monitoring that current clinical workflows are not designed to handle. Experience in the United States, where new Alzheimer’s treatments have been available for the past two years, serves as a warning. There, the immense logistical burden on clinics has limited adoption and created significant barriers to access, leaving many eligible patients unable to receive treatment.
“New treatments for Alzheimer’s disease are desperately needed,” said Dr. Andrew Frank, cognitive neurologist and researcher at Bruyère Health Research Institute, and CARE Initiative Principal Investigator. “When these new treatments come to Canada, we will require new tools to deliver treatment safely and in an accessible manner. The CARE Initiative is about proactively building and testing clinical infrastructure in Canada so we can successfully deliver these breakthroughs to patients.”
The Solution: A Coordination Platform for Alzheimer's Care
The Foresight™ platform acts as a coordination center for managing the entire patient journey, from diagnosis to treatment. It harmonizes the process from initial eligibility screening to long-term safety monitoring, empowering clinicians to:
- Support patient identification and eligibility
- Standardize complex treatment and monitoring protocols
- Securely track and manage potential side effects in real-time
- Coordinate care between clinics, brain imaging, and infusion centers
“Canada has the world-class clinical expertise to lead in Alzheimer’s care, but that expertise is fragmented,” said Dr. Christian Dansereau, CEO of Perceiv Research Inc. “Foresight™ provides the digital infrastructure to connect that expertise and create a national standard of care. This ensures every eligible Canadian has the same opportunity for timely and safe treatment.”
A National Initiative for Patient Safety and Research
Importantly, the CARE Initiative will also help shape a National Alzheimer’s Disease Treatment Registry, capable of monitoring the long-term safety and effectiveness of new Alzheimer’s treatments across Canada.
The Initiative is designed to improve safety and accessibility of all future Alzheimer's disease treatments. Eli Lilly Canada and Novo Nordisk Canada have provided foundational collaborative support, demonstrating a strong commitment to nationwide system readiness.
The Initiative welcomes collaboration from other pharmaceutical innovators and healthcare stakeholders who share the goal of building a robust, inclusive system of Alzheimer's disease treatment in Canada.
About Bruyère Health
Bruyère Health is Eastern Ontario’s leading health organization specializing in aging, rehabilitation, and care for those with multiple complex medical conditions. We bring together compassionate, person-centered care with world-class research to maximize quality of life for those we care for and their loved ones.
About Foresight™
Foresight™ is a Canadian-developed digital health platform designed to enhance patient safety and coordinate the complex Alzheimer's care journey. It provides clinical teams with a secure, nationwide system to standardize safety protocols and track patient outcomes in real-time. Foresight™ empowers clinicians to deliver groundbreaking therapies safely and effectively, improving the standard of patient care. Developed by Canadian-based Perceiv Research Inc., the platform is proudly hosted in Canada, ISO/IEC 27001:2022-certified, and fully PIPEDA compliant.
For media inquiries, please contact:
Jasmine Rooke
Bruyère Health Research Institute
JRooke@bruyere.org